LMAT LEMAITRE VASCULAR INC
Q3 2025 10-Q
Filed: Nov 7, 2025Period ending Sep 30, 2025
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR LEMAITRE VASCULAR INC (LMAT) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 7, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New product recall risk triggered by April 2025 inadequate seal issue on TufTex, Pruitt Occlusion, and Pruitt Irrigation catheters packaging
- • Updated regulatory risk: August 2025 FDA warning letter to Artegraft facility, no material financial impact or sales disruption reported
Quarterly Financial SummaryXBRL
Revenue
$61M
Net Income
$17M
Gross Margin
75.3%
Operating Margin
33.3%
Net Margin
28.4%
ROE
4.6%
Total Assets
$598M
Source: XBRL data from LEMAITRE VASCULAR INC Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on LEMAITRE VASCULAR INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.